Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medx Health Corp V.MDX

Alternate Symbol(s):  MDXHF

MedX Health Corp. is a medical device and software company. It develops and manufactures skin-related screening tools and phototherapy devices for pain relief and tissue repair. It focuses on skin health with its SIAscopy on DermSecure telemedicine platform, utilizing its SIAscopy technology. SIAscopy is a medical device technology that is used to scan skin for suspicious moles and lesions and, including DermSecure, its telemedicine software application, and phototherapeutic medical devices, which use light energy in lower-level laser and light-emitting diode to provide treatment of pain and tissue damage in the rehabilitation market. Its products SIAMETRICS, SIMSYS, and MoleMate include hand-held devices that use patented technology utilizing light and its remittance to view up to two millimeters beneath suspicious moles and lesions in a pain free, non-invasive manner. Its SIAscopy on DermSecure telemedicine platform enables the Web-based operation of its SIAscopy scanning technology.


TSXV:MDX - Post by User

Comment by hopefullon Oct 19, 2021 7:23am
95 Views
Post# 34021207

RE:Empower opening

RE:Empower opening
Attending the opening gave me a complete understanding of the model for Medx success. The empower deal IF successful will provide according to the Empower representative stating they will have close to 100 locations by the end of 2022 across the country. This alone should raise the market cap significantly, comparing the revenue of Dermtech. We literally are at the tipping point. Mike demonstrated the product well and took questions. Take aways were "there will be news releases over the next 6:to eight weeks announce many more pilots" according to Mike. Questions that I now come away with are 1. Does Medx get paid for scans during a pilot. 2. Once a pilot is determined to be successful how will that be measured by what metric. 3.will Medx provide followup news releases upon successful pilots and disclose the outcome. I ask these questions here as I hope someone might have already asked. With all that is moving there won't be much in the way of movement in share price until revenue from these deals start materializing in the finacials so my best guess is by q2 next year we will be in a whole different picture.
<< Previous
Bullboard Posts
Next >>